Shilpa Medicare Ltd
Dr. Jayant Karajgi currently serves as Chief Operating Officer at Shilpa Medicare Ltd since October 2019. Prior to this role, Dr. Karajgi held the position of COO at Rubicon Research Pvt Ltd from September 2017 to October 2019. Dr. Karajgi also served as Chief Scientific Officer at Wockhardt Ltd from June 2016 to August 2017 and as President at Aurobindo Pharma from July 2011 to June 2016. Dr. Karajgi holds a Master's degree in Pharmaceutical Sciences and a Doctor of Philosophy (PhD) in Novel Drug Delivery from the University of Sagar. Education was initiated at Carmel Convent School in Gwalior.
This person is not in any offices
Shilpa Medicare Ltd
Shilpa Medicare Limited is engaged in the business of manufacturing of bulk drugs or active pharmaceutical ingredient (API) and intermediates, and wind power generation. The Company's segments include Bulk Drug/Intermediates and Energy. It offers 3a 7b Dihydroxy. The Company deals with APIs, Intermediates, Formulations, New Drug Delivery Systems, Peptides/Biotech products and Specialty Chemicals. The Company supplies oncology/non-oncology APIs and intermediates. Its oncology API products include Anastrozole, Axitinib, Azacitidine, Abiraterone Acetate, Bicalutamide, Bortezomib, Busulphan, Cabazitaxel Amorphous, Capecitabine, Carboplatin, Cladribine, Clofarabine, Zoledronic acid, Vismodegib, Pemetrexed DiPotassium Nonahydrate, Cyclophosphamide Monohydrate and Cytarabine. It also offers AntiRetroVirals. Its non-oncology API products include Acebrophylline, Echothiophate, Nifedipine, Perfenidone, PrucaloprideSuccinate, Sildenafil Citrate, Ursodeoxycholic acid and Dimethyl Fumarate.